Adial Pharmaceuticals (ADIL) Accounts Payables (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Accounts Payables of $573567.0 for Q1 2026, down 12.46% sequentially from $655207.0 in Q4 2025, and up 7.73% YoY from $532430.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Accounts Payables (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Accounts Payables for 10 years, with the latest figure at $573567.0 in Q1 2026.
- Quarterly Accounts Payables rose 7.73% year-over-year to $573567.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $573567.0 (up 7.73% YoY) and the FY2025 annual result came in at $655207.0, up 161.95% from the prior year.
- Accounts Payables fell to $573567.0 in Q1 2026 per ADIL's latest filing, from $655207.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $671118.0 in Q2 2025 and troughed at $81925.0 in Q3 2023.
- A 5-year average of $380330.3 and a median of $318118.0 in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables slumped 81.92% in 2023, then jumped 288.3% in 2024.
- Over 5 years, Accounts Payables stood at $276410.0 in 2022, then tumbled by 62.62% to $103325.0 in 2023, then soared by 142.08% to $250130.0 in 2024, then jumped by 161.95% to $655207.0 in 2025, then dropped by 12.46% to $573567.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $573567.0, $655207.0, and $556284.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | 2.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 573,567.00 |
| Dec 31, 2025 | 655,207.00 |
| Sep 30, 2025 | 556,284.00 |
| Jun 30, 2025 | 671,118.00 |
| Mar 31, 2025 | 532,430.00 |
| Dec 31, 2024 | 250,130.00 |
| Sep 30, 2024 | 318,118.00 |
| Jun 30, 2024 | 316,726.00 |
| Mar 31, 2024 | 177,468.00 |
| Dec 31, 2023 | 103,325.00 |
| Sep 30, 2023 | 81,925.00 |
| Jun 30, 2023 | 111,702.00 |
| Mar 31, 2023 | 530,141.00 |
| Dec 31, 2022 | 276,410.00 |
| Sep 30, 2022 | 278,200.00 |
| Jun 30, 2022 | 617,778.00 |
| Mar 31, 2022 | 415,086.00 |
| Dec 31, 2021 | 286,192.00 |
| Sep 30, 2021 | 185,187.00 |
| Jun 30, 2021 | 477,411.00 |